Holen Sie sich die Stockscreener-App
3.91
4.63%
-0.19
Handel nachbörslich:
3.90
-0.01
-0.26%
Schlusskurs vom Vortag:
$4.10
Offen:
$4
24-Stunden-Volumen:
151.58K
Relative Volume:
0.79
Marktkapitalisierung:
$42.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.25M
KGV:
-2.1966
EPS:
-1.78
Netto-Cashflow:
$-17.87M
1W Leistung:
-1.26%
1M Leistung:
-14.44%
6M Leistung:
-0.51%
1J Leistung:
+2.62%
1-Tages-Spanne:
$3.85
$4.19
1-Wochen-Bereich:
$3.7375
$4.34
52-Wochen-Spanne:
$2.55
$6.118
Lantern Pharma Inc Stock (LTRN) Company Profile
Firmenname
Lantern Pharma Inc
Sektor
Branche
Telefon
972-277-1136
Adresse
1920 MCKINNEY AVENUE, DALLAS, TX
Vergleichen Sie LTRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.91 | 44.28M | 0 | -19.25M | -17.87M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.15 | 100.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.50 | 60.95B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.73 | 60.46B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
734.35 | 46.04B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.20 | 36.02B | 3.81B | -644.79M | -669.77M | -6.24 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-07 | Eingeleitet | H.C. Wainwright | Buy |
Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten
How to track smart money flows in Lantern Pharma Inc.July 2025 EndofMonth & Risk Controlled Daily Trade Plans - newser.com
Pattern recognition hints at Lantern Pharma Inc. upsideJuly 2025 Reactions & Verified Swing Trading Watchlist - newser.com
Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors - BioSpace
Using AI based signals to follow Lantern Pharma Inc.Weekly Stock Recap & Weekly High Conviction Trade Ideas - newser.com
Insider Sell: What are Lantern Pharma Incs recent SEC filings showingVolume Spike & Verified Entry Point Signals - خودرو بانک
Aug Spikes: Whats the beta of Lantern Pharma Inc stockEarnings Trend Report & Safe Entry Trade Signal Reports - خودرو بانک
Lantern Pharma (LTRN) Advances LP-184 with Positive Phase 1a Tri - GuruFocus
Lantern Pharma Says Phase 1a Study Of LP-184 Met All Primary Endpoints In Advanced Solid Tumors - Nasdaq
Lantern Pharma stock climbs after LP-184 cancer drug hits trial endpoints - Investing.com Canada
Aug Retail: Can Lantern Pharma Inc disrupt its industryQuarterly Profit Report & Stepwise Swing Trade Plans - خودرو بانک
Lantern Pharma's LP-184 Achieves Phase 1a Endpoints with 48% Clinical Benefit | LTRN Stock News - Stock Titan
Lantern Pharma Inc. stock prediction for this weekPortfolio Growth Summary & Weekly Breakout Watchlists - newser.com
What to do if you’re stuck in Lantern Pharma Inc.Risk Management & Stepwise Trade Signal Implementation - newser.com
Comparing Lantern Pharma Inc. in custom built stock radarsWeekly Investment Recap & Fast Entry Momentum Trade Alerts - newser.com
Forecasting Lantern Pharma Inc. price range with options dataWeekly Market Summary & Low Drawdown Investment Ideas - newser.com
Will earnings trigger a reversal in Lantern Pharma Inc.Market Growth Report & Community Trade Idea Sharing - newser.com
Intraday pattern recognizer results for Lantern Pharma Inc.Take Profit & Fast Entry High Yield Tips - newser.com
How to use Fibonacci retracement on Lantern Pharma Inc.Portfolio Risk Summary & Expert Curated Trade Setup Alerts - newser.com
Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma Featured on IBN’s BioMedWire Podcast - Barchart.com
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN) - The Manila Times
IBN Announces Latest Episode of The BioMedWire Podcast - GlobeNewswire
Lantern Pharma Inc. At Decision Level — Rebound or Resistance2025 Buyback Activity & Comprehensive Market Scan Reports - beatles.ru
Does Lantern Pharma Inc. align with a passive investing strategyJuly 2025 Selloffs & Technical Pattern Recognition Alerts - beatles.ru
Sentiment analysis tools applied to Lantern Pharma Inc.July 2025 Gainers & Weekly Breakout Opportunity Watchlist - Newser
CEO Change: How liquid is Lantern Pharma Inc. stockJuly 2025 PostEarnings & Growth Focused Stock Reports - خودرو بانک
Bear Alert: Can Lantern Pharma Inc. disrupt its industry2025 Trade Ideas & Verified Stock Trade Ideas - خودرو بانک
Can Lantern Pharma Inc. grow without dilution2025 Retail Activity & Stock Portfolio Risk Management - 더경남뉴스
Is Lantern Pharma Inc. stock trending bullishJuly 2025 Analyst Calls & Fast Exit Strategy with Risk Control - خودرو بانک
Lantern Pharma Inc. stock volume spike explainedTrade Risk Assessment & AI Powered Market Entry Ideas - Newser
Lantern Pharma Inc. stock chart pattern explained2025 Fundamental Recap & High Accuracy Investment Signals - Newser
Can Lantern Pharma Inc. lead its sector in growthQuarterly Trade Summary & AI Enhanced Execution Alerts - خودرو بانک
Hoth Therapeutics shares fall 2.24% premarket after adopting Lantern Pharma's AI-driven drug development tool. - AInvest
How sentiment analysis helps forecast Lantern Pharma Inc.Portfolio Return Report & Growth-Oriented Investment Plans - Newser
Using data tools to time your Lantern Pharma Inc. exitJuly 2025 Reactions & High Accuracy Investment Signals - Newser
Hoth Therapeutics shares fall 1.49% after-hours after adopting Lantern Pharma's AI-driven drug development tool. - AInvest
Lantern Pharma (NASDAQ: LTRN) Completes FDA Type C Meeting, Gains Guidance for Planned Pediatric CNS Cancer Trial - The Globe and Mail
Lantern Pharma shares fall 1.52% intraday after FDA meeting and Hoth Therapeutics partnership. - AInvest
AI-Driven Drug Development: Hoth Therapeutics and Lantern Pharma’s Strategic Partnership to Revolutionize CNS Therapies - AInvest
Lantern Pharma's PredictBBB.ai Platform to Drive Next-Gen Drug Development with Hoth Therapeutics Partnership - AInvest
94% Accurate AI Platform: Hoth Therapeutics Taps Revolutionary Blood-Brain Barrier Prediction Technology - Stock Titan
Detecting support and resistance levels for Lantern Pharma Inc.CEO Change & Smart Swing Trading Alerts - Newser
What data driven models say about Lantern Pharma Inc.’s future2025 Breakouts & Breakdowns & Safe Entry Zone Identification - Newser
Will breakout in Lantern Pharma Inc. lead to full recoveryBear Alert & Fast Moving Stock Trade Plans - Newser
Lantern Pharma Receives FDA Guidance for Pediatric CNS Cancer Trial of AI-Discovered Therapy - citybuzz -
Automated trading signals detected on Lantern Pharma Inc.Market Movement Recap & Detailed Earnings Play Alerts - Newser
Lantern Pharma announces completion of Type C meeting with FDA - MSN
Lantern Pharma receives FDA feedback on pediatric brain cancer trial - Investing.com
Lantern Pharma receives FDA feedback on pediatric brain cancer trial By Investing.com - Investing.com UK
Lantern Pharma Completes FDA Type C Meeting, Advances Pediatric CNS Cancer Trial with FDA Guidance - AInvest
Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial - Business Wire
Top chart patterns to watch in Lantern Pharma Inc.July 2025 Review & Daily Chart Pattern Signals - Newser
Finanzdaten der Lantern Pharma Inc-Aktie (LTRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.62%
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):